Literature DB >> 7710924

Interleukin 12: a new clinical player in cytokine therapy.

R E Banks, P M Patel, P J Selby.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7710924      PMCID： PMC2033718          DOI： 10.1038/bjc.1995.130

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  68 in total

1.  Regulation of human cytolytic lymphocyte responses by interleukin-12.

Authors:  M K Gately; A G Wolitzky; P M Quinn; R Chizzonite
Journal:  Cell Immunol       Date:  1992-08       Impact factor: 4.868

2.  Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.

Authors:  B Perussia; S H Chan; A D'Andrea; K Tsuji; D Santoli; M Pospisil; D Young; S F Wolf; G Trinchieri
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

3.  IL-12 augments antigen-dependent proliferation of activated T lymphocytes.

Authors:  M M Bertagnolli; B Y Lin; D Young; S H Herrmann
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

Review 4.  Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1992-10

5.  IL-12 receptor. II. Distribution and regulation of receptor expression.

Authors:  B B Desai; P M Quinn; A G Wolitzky; P K Mongini; R Chizzonite; M K Gately
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

6.  IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts.

Authors:  R Chizzonite; T Truitt; B B Desai; P Nunes; F J Podlaski; A S Stern; M K Gately
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

7.  Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5.

Authors:  D Sieburth; E W Jabs; J A Warrington; X Li; J Lasota; S LaForgia; K Kelleher; K Huebner; J J Wasmuth; S F Wolf
Journal:  Genomics       Date:  1992-09       Impact factor: 5.736

8.  Cloning and expression of murine IL-12.

Authors:  D S Schoenhaut; A O Chua; A G Wolitzky; P M Quinn; C M Dwyer; W McComas; P C Familletti; M K Gately; U Gubler
Journal:  J Immunol       Date:  1992-06-01       Impact factor: 5.422

9.  Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes.

Authors:  M Kiniwa; M Gately; U Gubler; R Chizzonite; C Fargeas; G Delespesse
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

10.  Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.

Authors:  A D'Andrea; M Rengaraju; N M Valiante; J Chehimi; M Kubin; M Aste; S H Chan; M Kobayashi; D Young; E Nickbarg
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more
  8 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12.

Authors:  D Popovic; K M El-Shami; E Vadai; M Feldman; E Tzehoval; L Eisenbach
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 4.  The rationale and future potential of angiogenesis inhibitors in neoplasia.

Authors:  G Gasparini
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Authors:  Elizabeth W Sorensen; Scott A Gerber; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2010-01-08       Impact factor: 5.422

7.  Serum IL-8 and IL-12 levels in breast cancer.

Authors:  Duygu Derin; Hilal Oguz Soydinc; Nese Guney; Faruk Tas; Hakan Camlica; Derya Duranyildiz; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.

Authors:  P Lissoni; L Fumagalli; F Rovelli; F Brivio; G Di Felice; F Majorca
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.